Advertisement

Picture EBD Group BIO-Europe Spring 2021 Digital 650x80

Deals > All

Total search results: 6291 | Ordered by Date (descending)
1 2 3 ... 61 62 63  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cognate BioServices–Charles River: investment, 202102– acquisition $875m in cash by Charles River ANNOUNCED 2021-02-17
Ginolis–Cellink: investment, 202102– acquisition 100% of Ginolis for €70m with €42m in cash + €28m in shares ANNOUNCED 2021-02-15
Sophia Genetics–Gilmartin Group: public relations, 202102 service existent Gilmartin Group is investor contact 2021-02-11
SpyBiotech–Alphabet: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor GV 2021-02-10
SpyBiotech–Braavos Investment Advisors: investment, 202102 financing round Series A totalling $32.5m incl new + lead investor Braavos 2021-02-10
SpyBiotech–Oxford Investment Consultants: investment, 202102 financing round Series A totalling $32.5m incl new + co-investor OIC 2021-02-10
SpyBiotech–SEVERAL: investment, 202102 financing round Series A $32.5m led by new investor Braavos Investment Advisers 2021-02-10
SpyBiotech–United Kigdom (govt): investment, 202102 financing round Series A totalling $32.5m incl Future Fund converting prior convertible loan 2021-02-10
SpyBiotech–Univ Oxford: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor Oxford Sciences Innovation 2021-02-10
Pan Cancer T–Netherlands (govt): grant, 202102 Health~Holland grant for public-private-partnership with Erasmus Medical Center 2021-02-08
Pan Cancer T–SEVERAL: investment, 202102 seed financing round from Swanbridge Capital + Van Herk Ventures 2021-02-08
Pan Cancer T–Swanbridge Capital: investment, 202102 seed financing round incl investor Swanbridge Capital 2021-02-08
Pan Cancer T–Van Herk: investment, 202102 seed financing round incl investor Van Herk Ventures 2021-02-08
InfanDx–Akampion: public relations, 202102 service existent by Akampion 2021-02-04
PepGen–Verge Scientific Communications: public relations, 202102 service existent by Verge 2021-02-04
Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets 2021-02-04
V-Bio Ventures–SEVERAL: investment, 202102 first closing €78m capital commitments for new V-Bio Ventures Fund 2 2021-02-04
Abingworth–Huntsworth: public relations, 202102 service existent by Citigate Dewe Rogerson 2021-02-03
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund 2021-02-03
GW Pharmaceuticals–Jazz Pharmaceuticals: investment, 202102– acquisition $7.2b at $220/ADS with $200 in cash + $20 in ordinary shares ANNOUNCED 2021-02-03
Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy 2021-02-02
Avacta–Adeptrix: MS-based SARS-CoV-2 test, 202101 collab existent developm of BAMS SARS-CoV-2 assay for research + IVD 2021-01-28
Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test 2021-01-28
BiondVax–SEVERAL: investment, 202101– Pulbic Offering $12m+$1.8m with 2.4m+365k ADSs at $4.95/ADS 2021-01-28
Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund 2021-01-28
Lauxera Capital–SEVERAL: investment, 2020–2021 launch of €100m fund incl investors Bpifrance + Covéa + Téthys + CNP et al 2021-01-27
GeneQuine–Brandenburg (govt): grant, 202101 grant €900k from investment bank of federal state Brandenburg 2021-01-26
GeneQuine–High-Tech Gründerfonds: investment, 202101 financing round Series A totalling €5.4m incl existing + co-investor HTGF 2021-01-26
GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA 2021-01-26
GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences 2021-01-26
GeneQuine–Samum: credit, 202101 convertible loans totalling €2.75m from Pacira BioSciences Inc + Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–Samum: investment, 202101 financing round Series A totalling €5.4m incl co-investor Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences 2021-01-26
Minoryx–Image Box: public relations, 202101 service existent by Image Box Communications 2021-01-26
Cellvie–Forever Healthy: investment, 202101 seed financing round totalling $5m incl lead investor Kizoo Technology Capital 2021-01-25
Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital 2021-01-25
CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share 2021-01-25
Lift BioSciences–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
Omnix Medical–EU (govt): grant, 202101– funding €10.8m under EIC Accelerator Programme to advance antibiotic OMN6 2021-01-25
TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund 2021-01-25
TScan Therapeutics–Pitango: investment, 202101 financing round Series C totalling $100m incl existing investor Pitango HealthTech 2021-01-25
TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital 2021-01-25
Servier–MiNA Therapeutics: saRNA therapeutics, 202101– collab research + license option for saRNA therapeutics for neurological diaseses 2021-01-21
AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones 2021-01-20
Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.5m at Nasdaq 2021-01-20
Neurent Medical–Atlantic Bridge: investment, 202101 financing round Series B totalling €21m incl co-lead investor Atlantic Brdige Growth Fund IV 2021-01-20
Neurent Medical–Fountain Healthcare Partners: investment, 202101 financing round Series B totalling €21m incl existing + co-investor Fountain HP 2021-01-20
Neurent Medical–Life Sciences Partners: investment, 202101 financing round Series B totalling €21m incl lead investor LSP Health Economics Fund 2 2021-01-20
Neurent Medical–SEVERAL: investment, 202101 financing round Series B €21m led by LSP Health Economics Fund 2 2021-01-20
Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services 2021-01-20
ConserV Bioscience–Optimum Strategic Communications: public relations, 202101 service existent by Optimum 2021-01-19
ConserV Bioscience–United States (govt): coronavirus vaccine, 202101– collab developm broad spectrum coronvirus vaccine using NLP technology from LLNL 2021-01-19
CoviCept Therapeutics–Forbion: investment, 202101 seed investment $2.3 from Forbion 2021-01-19
Merus–SEVERAL: investment, 202101 public offering $120m+$18m with 4.85m+727.3k common shares at $24.75/share 2021-01-19
Slate Bio–Epidarex Capital: investment, 202101 seed financing round totalling $1.75m incl lead investor Epidarex Capital 2021-01-19
Slate Bio–SEVERAL: investment, 202101 seed financing round $1.75m led by Epidarex Capital 2021-01-19
LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH 2021-01-18
LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF 2021-01-18
LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG 2021-01-18
LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG 2021-01-18
Novasep–Thermo Fisher: investment, 202101 acquisition €725m in cash of viral vector manufacturing business Henogen SA in Belgium by Thermo Fisher 2021-01-15
NewAmsterdam Pharma–SEVERAL: investment, 202101 financing round Series A €160m co-led by Morningside Ventures + Ascendant BioCapital 2021-01-14
IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments 2021-01-13
Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors 2021-01-13
Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share 2021-01-12
Sanofi–Biond Biologics: antibody cancer drug, 202101– license ww excl to BND-22 anti-IgG4 antibody $125m upfront + >$1b milestones + royalties 2021-01-12
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based 2021-01-11
Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI 2021-01-11
Immunocore–BlackRock: investment, 202101 financing round Series C totalling $75m incl funds + accounts managed by BlackRock 2021-01-11
Immunocore–SEVERAL: investment, 202101 financing round Series C $75m incl funds + accounts managed by BlackRock 2021-01-11
Immunocore–Wafra: credit, 202101– senior secured loan facility $100m from Oxford Finance LLC 2021-01-11
Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED 2021-01-11
Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag 2021-01-11
Labforward–Peppermint: investment, 202101 financing round Series B totalling >€5m incl existing + co-investor Peppermint VenturePartners 2021-01-11
Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners 2021-01-11
Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake 2021-01-11
Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP 2021-01-11
Valo Health–Canada (govt): investment, 202101 financing round Series B totalling $190m incl lead investor PSP Investments 2021-01-11
Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments 2021-01-11
Valo Health–SEVERAL: investment, 202101 financing round Series B $190m led by PSP Investments 2021-01-11
Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies 2021-01-08
AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck 2021-01-07
BioGeneration Ventures–BMS: investment, 202101 final closing of BGV IV totalling €140m incl investor BMS 2021-01-07
BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund 2021-01-07
BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital 2021-01-07
BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension 2021-01-07
BioGeneration Ventures–Instinctif Partners: public relations, 202101 service existent by Instinctif 2021-01-07
BioGeneration Ventures–Lilly: investment, 202101 final closing of BGV IV totalling €140m incl investor Eli Lilly 2021-01-07
BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures 2021-01-07
BioGeneration Ventures–Schroders: investment, 202101 final closing of BGV IV totalling €140m incl investor Schroder Adveq 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies 2021-01-07
Oxford Immunotec–PerkinElmer: investment, 202101– acquisition $591m with $22/share in cash ANNOUNCED 2021-01-07
Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m 2021-01-07
Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp 2021-01-06
Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp 2021-01-06
Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 2021-01-06
Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare 2021-01-05
Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare 2021-01-05
1 2 3 ... 61 62 63  next pagenext page



Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top